RECITE: Revising Eligibility Criteria Incorporating Textual Evidence
Read the original on arXiv AI →The Flow has not summarised this story yet — read it at arXiv AI.
The Flow has not summarised this story yet — read it at arXiv AI.
arXiv:2609.01202v1 Announce Type: cross Abstract: Clinical trials are essential for advancing cancer care and drug development, but many fail because of insufficient patient enrollment. While there i...
The paper introduces a retrieval‑augmented multi‑agent framework that automatically generates instance‑specific evaluation rubrics for medical language models. By retrieving authoritative medical evidence, decomposing it into atomic facts, and combining these with user interaction constraints, the system produces fine‑grained criteria that outperform GPT‑4o on HealthBench and LLMEval‑Med. The generated rubrics also guide response refinement, improving medical LLM output quality by 9.2%.
arXiv:2609.21859v1 Announce Type: new Abstract: Nearly 90% of drugs entering clinical development ultimately fail, despite billions of dollars in investment. Pharmaceutical companies therefore rely o...
arXiv:2608.22062v1 Announce Type: new Abstract: Longitudinal clinical event-relation verification determines whether a patient record supports a specified relation among two or more clinical events....
arXiv:2608. 07796v1 Announce Type: new Abstract: Large language models perform strongly on medical knowledge benchmarks, but reliable clinical deployment requires agents to conduct defensible investigations over heterogeneous, longitudinal records: determining what evidence is needed, retrieving and reconciling structured and free-text data, grounding conclusions in verifiable evidence, and deferring cases that cannot be resolved reliably.
FD‑SCoPE is a language‑model framework that answers clinicians’ questions about systematic review evidence tables, exposing the underlying query, selected trials, and derivation rule for each answer. It handles both directly recorded attributes and derived attributes, achieving high accuracy on an oncology evidence table of 159 immune‑checkpoint inhibitor trials. After incorporating expert corrections, its performance on unseen questions improved from 77.9% to 84.9% F1.